You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 8, 2024

Litigation Details for Journey Medical Corporation v. Padagis Israel Pharmaceuticals, Ltd. (D. Del. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Journey Medical Corporation v. Padagis Israel Pharmaceuticals, Ltd. (D. Del. 2021)

Docket ⤷  Sign Up Date Filed 2021-08-09
Court District Court, D. Delaware Date Terminated 2022-05-19
Cause 35:271 Patent Infringement Assigned To Colm Felix Connolly
Jury Demand None Referred To
Parties VYNE THERAPEUTICS INC.
Patents 10,086,080; 10,137,200; 10,213,512; 10,265,404; 10,398,641; 10,517,882; 8,865,139; 8,945,516; 8,992,896; 9,675,700
Attorneys Jonathan R. Davies
Firms Shaw Keller LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Journey Medical Corporation v. Padagis Israel Pharmaceuticals, Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷  Sign Up and ⤷  Sign Up .
Biologic Drugs cited in Journey Medical Corporation v. Padagis Israel Pharmaceuticals, Ltd.
The biologic drug covered by the patents cited in this case is ⤷  Sign Up .

Details for Journey Medical Corporation v. Padagis Israel Pharmaceuticals, Ltd. (D. Del. 2021)

Date Filed Document No. Description Snippet Link To Document
2021-08-09 1 Complaint (“the ’896 patent”); 9,675,700 (“the ’700 patent”); 10,086,080 (“the ’080 patent”); 10,137,200 (“the… COUNT IX – INFRINGEMENT OF U.S. PATENT NO. 10,086,080 93. Plaintiff fully incorporate…’139 patent, the ’516 patent, the ’896 patent, the ’700 patent, the ’080 patent, the ’200 patent, the…’139 patent, the ’516 patent, the ’896 patent, the ’700 patent, the ’080 patent, the ’200 patent, the…’139 patent, the ’516 patent, the ’896 patent, the ’700 patent, the ’080 patent, the ’200 patent, the External link to document
2021-08-09 3 ANDA Form Expiration of Patent: Patent Nos. 8,865,139; 8,945,516; 8,992,896; 9,675,700; 10,086,080; 10,137,200; … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …10,517,882; and 10,821,187 expire on 10/01/2030. Patent Nos. 10,398,641 and 10,849,847 will expire on 09… 2021 19 May 2022 1:21-cv-01152 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2021-08-09 4 Patent/Trademark Report to Commissioner of Patents ;8,945,516 B2 ;8,992,896 B2 ;9,675,700 B2 ;10,086,080 B2 ;10,137,200 B2 ;10,213,512 B2 ;10,265,404 B2… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,865,139 B1 ;… 2021 19 May 2022 1:21-cv-01152 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2022-05-19 45 Patent/Trademark Report to Commissioner of Patents ; 8,945,516 B2; 8,992,896 B2; 9,675,700 B2; 10,086,080 B2. (Attachments: # 1 Stipulation of Dismissal)… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,865,139 B1; … 2021 19 May 2022 1:21-cv-01152 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.